A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Status:
Recruiting
Trial end date:
2024-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants
with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms
and inflammation.